ALP

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Retrieved on: 
Monday, April 1, 2024
MELD, Metabolism, Regeneration, Dicarboxylic acid, Survival, Liver disease, PD, Safety, Patient, History, Alkaline phosphatase, CYP1A2, Crosstalk (biology), ASGR1, Pharmacokinetics, Therapy, ALP, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today provided an update on the Phase 1a clinical trial of SZN-043 in healthy volunteers and patients with cirrhosis.   The Phase 1a study was completed in February 2024. SZN-043 demonstrated acceptable safety and tolerability in all subjects, with evidence of target engagement, Wnt signal activation and effects on liver function.   The observed safety and pharmacodynamic activity were the basis for the Company’s previous announcement that it planned to initiate enrollment in the Phase 1b study in alcohol-associated hepatitis.

Key Points: 
  • SZN-043 demonstrated acceptable safety and tolerability in all subjects, with evidence of target engagement, Wnt signal activation and effects on liver function.
  • The observed safety and pharmacodynamic activity were the basis for the Company’s previous announcement that it planned to initiate enrollment in the Phase 1b study in alcohol-associated hepatitis.
  • The randomized, placebo-controlled Phase 1a trial enrolled a total of 48 subjects, including 40 healthy volunteers and 8 patients with cirrhosis and a history of liver disease.
  • Cirrhotic patients also showed evidence of liver function effects after treatment with SZN-043 as measured by HepQuant which is a test that measures cholate clearance, a liver specific function that quantifies liver function.

German manufacturer Karcher opens regional distribution centre at Tatu City, Kenya

Retrieved on: 
Wednesday, March 27, 2024
Ambassador, Republic, Equipment, Partnership, Davis & Shirtliff, Karcher, CCI, Food, Investment, VAT, Engineering, Carrefour, USD, ALP, Heineken, FFS, Property management

TATU CITY, Kenya, March 27, 2024 /PRNewswire/ -- German-based cleaning equipment manufacturer Karcher has announced an approximate €3 million investment in the Kenyan market. The move was made to operationalize the business into a full subsidiary, which includes a regional distribution centre at Freight Forwarders Solutions (FFS) in Tatu City, the 5,000-acre mixed-use Special Economic Zone (SEZ) on Nairobi's doorstep, positioning Kenya as a hub for East Africa.

Key Points: 
  • TATU CITY, Kenya, March 27, 2024 /PRNewswire/ -- German-based cleaning equipment manufacturer Karcher has announced an approximate €3 million investment in the Kenyan market.
  • By establishing Kenya as our regional hub, we are reducing lead times and enhancing responsiveness, ensuring prompt service and satisfaction for our clients."
  • Stephen Jennings, Founder & CEO of Rendeavour, the owner and developer of Tatu City, added, "Karcher joins the ranks of many leading global brands at Tatu City SEZ.
  • The company that provides warehouse operations for Karcher in Kenya, FFS, has an international-standard logistics and distribution hub in Tatu Industrial Park.

German manufacturer Karcher opens regional distribution centre at Tatu City, Kenya

Retrieved on: 
Wednesday, March 27, 2024
Ambassador, Republic, Equipment, Partnership, Davis & Shirtliff, Karcher, CCI, Food, Investment, VAT, Engineering, Carrefour, USD, ALP, Heineken, FFS, Property management

TATU CITY, Kenya, March 27, 2024 /PRNewswire/ -- German-based cleaning equipment manufacturer Karcher has announced an approximate €3 million investment in the Kenyan market. The move was made to operationalize the business into a full subsidiary, which includes a regional distribution centre at Freight Forwarders Solutions (FFS) in Tatu City, the 5,000-acre mixed-use Special Economic Zone (SEZ) on Nairobi's doorstep, positioning Kenya as a hub for East Africa.

Key Points: 
  • TATU CITY, Kenya, March 27, 2024 /PRNewswire/ -- German-based cleaning equipment manufacturer Karcher has announced an approximate €3 million investment in the Kenyan market.
  • By establishing Kenya as our regional hub, we are reducing lead times and enhancing responsiveness, ensuring prompt service and satisfaction for our clients."
  • Stephen Jennings, Founder & CEO of Rendeavour, the owner and developer of Tatu City, added, "Karcher joins the ranks of many leading global brands at Tatu City SEZ.
  • The company that provides warehouse operations for Karcher in Kenya, FFS, has an international-standard logistics and distribution hub in Tatu Industrial Park.

ICP DAS-BMP Secures Pivotal TPU Deals with Medical Materials Leaders in U.S. and Japan, Boosts Product Reliability

Retrieved on: 
Tuesday, March 19, 2024
DAS, Hardness, Plasticizer, ARC, ESG, PICC, Barium sulfate, ICP, ALP, ALC, Research, Volatile organic compound, ARP, Plastic, TPU, Medical device

ICP DAS-BMP, Asia's first medical-grade TPU supplier, produces three main series of products: Alithane™ (ALP series), Durathane™ (ALC series), and Arothane™ (ARP series).

Key Points: 
  • ICP DAS-BMP, Asia's first medical-grade TPU supplier, produces three main series of products: Alithane™ (ALP series), Durathane™ (ALC series), and Arothane™ (ARP series).
  • All the TPU series are available in different hardness levels, colors, and concentrations of radiopaque fillers (Tungsten/Barium Sulfate).
  • These materials are widely utilized in manufacturing cardiovascular, urological, and gastrointestinal devices, as well as medical and electromedical consumables.
  • ICP DAS-BMP aims to offer safer, stable, and eco-friendly medical-grade TPU, collaborating with global medical device manufacturers to create long-term benefits and value.

ICP DAS-BMP Secures Pivotal TPU Deals with Medical Materials Leaders in U.S. and Japan, Boosts Product Reliability

Retrieved on: 
Tuesday, March 19, 2024
DAS, Hardness, Plasticizer, ARC, ESG, PICC, Barium sulfate, ICP, ALP, ALC, Research, Volatile organic compound, ARP, Plastic, TPU, Medical device

ICP DAS-BMP, Asia's first medical-grade TPU supplier, produces three main series of products: Alithane™ (ALP series), Durathane™ (ALC series), and Arothane™ (ARP series).

Key Points: 
  • ICP DAS-BMP, Asia's first medical-grade TPU supplier, produces three main series of products: Alithane™ (ALP series), Durathane™ (ALC series), and Arothane™ (ARP series).
  • All the TPU series are available in different hardness levels, colors, and concentrations of radiopaque fillers (Tungsten/Barium Sulfate).
  • These materials are widely utilized in manufacturing cardiovascular, urological, and gastrointestinal devices, as well as medical and electromedical consumables.
  • ICP DAS-BMP aims to offer safer, stable, and eco-friendly medical-grade TPU, collaborating with global medical device manufacturers to create long-term benefits and value.

Altera Infrastructure announces strategic divestment of ALP Maritime Services

Retrieved on: 
Friday, March 1, 2024
Investment, Sale, ALP, AHT, Carbon, CCS, FPSO

WESTHILL, United Kingdom, March 01, 2024 (GLOBE NEWSWIRE) -- Altera Infrastructure L.P. (Altera), one of the world’s leading suppliers of infrastructure assets to the offshore energy industry, today announced that they have divested ALP Maritime Group B.V., together with all its subsidiaries (ALP).

Key Points: 
  • WESTHILL, United Kingdom, March 01, 2024 (GLOBE NEWSWIRE) -- Altera Infrastructure L.P. (Altera), one of the world’s leading suppliers of infrastructure assets to the offshore energy industry, today announced that they have divested ALP Maritime Group B.V., together with all its subsidiaries (ALP).
  • The sale of this world class fleet of anchor handling tug (AHT) vessels also offers ALP further development opportunities under new and experienced ownership.
  • Together we have grown ALP to become the market leader in its field, performing over 350 projects while being under the umbrella of Altera.
  • We are sure that these vessels and the crew sailing them will make next owners as proud as they have made us,” said Paul Mulder, CEO of ALP.

Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS

Retrieved on: 
Thursday, February 29, 2024
ALS Association, Senior, ALS, Research, Alzheimer's disease, TFEB, Wang, Neuron, ALP, Hope, Trehalose, Neurodegenerative disease, Protein, Patient, Spinal cord, Gene, Disease, CSO, Diagnosis, Autophagy, AAV, Amyotrophy, Brain

The grant, which will support the development of Coave’s CTx-TFEB program through to preclinical proof-of-concept, has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program .

Key Points: 
  • The grant, which will support the development of Coave’s CTx-TFEB program through to preclinical proof-of-concept, has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program .
  • ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.
  • Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe.
  • With this funding and invaluable support from the ALS Association, we are poised to move our CTx-TFEB program forward.

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, February 28, 2024
Alkaline phosphatase, Acquisition, Liver, Child, Therapy, EMA, Ursodeoxycholic acid, New Drug Application, Gilead Sciences, Education, IDEAL, FDA, Science, Quality of life, Food, Marketing, U.S. FDA, Breakthrough, ALP, Hospital, PBC, Phase 3, Cirrhosis, Hepatology, Seladelpar, Safety, ULN, European Medicines Agency, Numerical, Patient, MHRA, UDCA, Itch, NDA, NRS, Pharmaceutical industry

NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2023.

Key Points: 
  • NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2023.
  • “2023 was a seminal year for CymaBay with critical achievements in the development of our investigational therapeutic, seladelpar.
  • Net loss for the year ended December 31, 2023 and 2022 was $105.4 million and $106.0 million, or ($0.99) and ($1.21) per share, respectively.
  • Net loss for the three months ended December 31, 2023 was higher than the three months ended December 31, 2022 primarily due to higher operating expenses.

ChampionX acquires Artificial Lift Performance Limited to expand digital solutions portfolio

Retrieved on: 
Tuesday, February 27, 2024
Theta, Acquisition, ALP, Life, Pump, Software

THE WOODLANDS, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) announced today the acquisition of Artificial Lift Performance Limited (“ALP”), a provider of advanced analytics solutions for enhancing oil and gas production performance.

Key Points: 
  • THE WOODLANDS, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) announced today the acquisition of Artificial Lift Performance Limited (“ALP”), a provider of advanced analytics solutions for enhancing oil and gas production performance.
  • Based in Edinburgh, Scotland, ALP has extensive expertise in developing artificial lift optimization software designed to maximize production and extend the life of artificial lift equipment.
  • “The acquisition of Artificial Lift Performance is key to our strategic focus on digital growth and our vision to deliver end-to-end digital solutions that enhance the productivity and profitability of our customers’ producing assets,” said Paul Mahoney, President of ChampionX’s Production & Automation Technologies (“PAT”) business segment.
  • “ChampionX and ALP have a shared vision for creating a true digital oil field, backed by a technology roadmap rooted in customer needs and opportunities in the market.

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

Retrieved on: 
Monday, February 12, 2024
Alkaline phosphatase, Liver, Child, Ursodeoxycholic acid, New Drug Application, BTD, Cirrhosis, Inflammation, FDA, Quality of life, Food, Breakthrough, Chief, Conditional sentence, PDUFA, ALP, PBC, Seladelpar, Therapy, Fatigue, Patient, Itch, Mortality, NDA, Pharmaceutical industry

NEWARK, Calif., Feb. 12, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for seladelpar, an investigational treatment for the management of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid. The FDA has granted priority review and set a Prescription Drug User Fee Act (PDUFA) target action date of August 14, 2024 and notified the company that it is not currently planning to hold an advisory committee meeting to discuss the application.

Key Points: 
  • PBC is a rare, chronic condition that can lead to inflammation and eventually liver cirrhosis.
  • People living with PBC can also experience symptoms that significantly impact their quality of life such as pruritus (itch) and fatigue.
  • Seladelpar is an investigational, potent, selective, orally active PPARδ agonist, or delpar, in development for PBC treatment.
  • "We are encouraged by the agency's decision to grant priority review for seladelpar, and its recognition of the significant need for new treatment options for people living with PBC.